Johnson & Johnson to acquire Actelion for $30 billion with spin-out of new R&D company | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 25 January, 2017 by The TZ Newswire Staff

Johnson & Johnson to acquire Actelion for $30 billion with spin-out of new R&D company

Swiss biotech company Actelion said on Thursday it had agreed to be purchased by Johnson & Johnson in a $30 billion deal.

See also
- Next Article China’s Li says his country offers an anchor of stability and growth in an uncertain world
- Previous Article USDJPY on a charge to new session highs
Editorial Calender

January 2017

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30 31

« Dec Feb »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar